The Moneybeat crew tries to answer the looming questions that remain after Valeant Pharmaceuticals plays defense. Plus, does the market think it has the Fed in its pocket? And whether or not the iPhone 6s will boost earnings for Apple.

Learn more about your ad choices. Visit megaphone.fm/adchoices